ITI214 is a potent and selective phosphodiesterase 1 (PDE1) inhibitor, primarily investigated for its potential therapeutic applications in neurological and psychiatric disorders. Its ability to modulate cyclic nucleotide signaling pathways makes it a promising candidate for addressing cognitive impairments and neuroinflammation. Research has focused on its use in conditions such as Parkinson’s disease, where it may help improve motor and cognitive symptoms by enhancing dopamine signaling and reducing neuronal dysfunction. Additionally, ITI214 is being explored for its potential in treating schizophrenia, as it may mitigate cognitive deficits associated with the disorder. Its anti-inflammatory properties also suggest potential applications in neurodegenerative diseases like Alzheimer’s, where it could help slow disease progression by reducing neuroinflammation and promoting neuronal health. Preclinical and clinical studies continue to evaluate its efficacy and safety in these areas.